The EnMed program is housed out of the Texas A&M University System's new Discovery Tower in the Texas Medical Center. Image via Facebook/TAMU EnMEd

Priya Arunachalam knew that she had a calling to heal, but she also has a mind for solving problems. After earning a B.S. in biomedical engineering and an MBA in healthcare management and entrepreneurship from Johns Hopkins University, the Austin native applied to medical schools knowing that her trajectory would be working as “a doctor-plus,” as she puts it.

Fortunately, a new program that combined the powers of Houston Methodist and Texas A&M University was recruiting its first graduating class. The School of Engineering Medicine allows students to simultaneously earn both a medical doctorate and a master of engineering degree in four years. It was the perfect fit.

On May 19, she will be among the 22 first students to earn those degrees. Five of them are staying on at Houston Methodist and Arunachalam is one of them.

“I am doing a general surgery residency at Houston Methodist. I am leaning towards transplant,” Arunachalam tells InnovationMap.

It’s no easy task to become a member of the EnMed program, as it’s informally known. Classes are capped at just 50 students a year, says Dr. Timothy Boone, director of education at Houston Methodist Academic Institute. He says that in the four years since EnMed launched, the size and diversity of the applicant pool has continued to grow, but it’s a very specific type of student they’re looking for.

Students must have an undergraduate degree in engineering, for one. That, Boone says, attracts problem solvers who also want to practice medicine.

“If you just think of it as a job, you’re in it for the wrong reasons,” he says.

Throughout their four years of education, students put their problem solving to the test. As they learn about medicine, the students see issues at a patient level and come up with engineering solutions.

One of Arunachalam’s creations in her time in EnMed was a redesigned hospital gown that allows for exams despite being less exposed in the back. She’s currently trying to pilot them at Houston Methodist Hospital.

Boone also mentions an ophthalmology student who has gained a preliminary patent on a design for a chair that accommodates more body types than those currently being used by most doctors. Another group of students created Go Baby Go, a toy car specifically designed for children with significant mobility impairment.

EnMed isn’t Houston Methodist’s only innovative collaboration. The University of St. Thomas Cameron School of Business joins forces with Houston Methodist to offer a master in clinical translation management program to teach students how to turn their ideas into thriving companies.

With Arunachalam’s business background, one might have expected her to follow such a path. But she says she prefers to create solutions and “find the right teams to take those ideas forward.”

Instead, her future is in surgery, which she says, is its own kind of engineering.

“I think they’re very similar," she says. "In engineering, we take apart a problem and put it back together a little better. In surgery you have a system that is malfunctioning and we have to find novel ways to fix it.”

And her and her classmates’ novel discoveries will soon be helping countless patients.

The EnMed program is graduating its first class this week. Photo via HoustonMethodist.org

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

Houston company plans lunar mission to test clean energy resource

lunar power

Houston-based natural resource and lunar development company Black Moon Energy Corporation (BMEC) announced that it is planning a robotic mission to the surface of the moon within the next five years.

The company has engaged NASA’s Jet Propulsion Laboratory (JPL) and Caltech to carry out the mission’s robotic systems, scientific instrumentation, data acquisition and mission operations. Black Moon will lead mission management, resource-assessment strategy and large-scale operations planning.

The goal of the year-long expedition will be to gather data and perform operations to determine the feasibility of a lunar Helium-3 supply chain. Helium-3 is abundant on the surface of the moon, but extremely rare on Earth. BMEC believes it could be a solution to the world's accelerating energy challenges.

Helium-3 fusion releases 4 million times more energy than the combustion of fossil fuels and four times more energy than traditional nuclear fission in a “clean” manner with no primary radioactive products or environmental issues, according to BMEC. Additionally, the company estimates that there is enough lunar Helium-3 to power humanity for thousands of years.

"By combining Black Moon's expertise in resource development with JPL and Caltech's renowned scientific and engineering capabilities, we are building the knowledge base required to power a new era of clean, abundant, and affordable energy for the entire planet," David Warden, CEO of BMEC, said in a news release.

The company says that information gathered from the planned lunar mission will support potential applications in fusion power generation, national security systems, quantum computing, radiation detection, medical imaging and cryogenic technologies.

Black Moon Energy was founded in 2022 by David Warden, Leroy Chiao, Peter Jones and Dan Warden. Chiao served as a NASA astronaut for 15 years. The other founders have held positions at Rice University, Schlumberger, BP and other major energy space organizations.

Houston co. makes breakthrough in clean carbon fiber manufacturing

Future of Fiber

Houston-based Mars Materials has made a breakthrough in turning stored carbon dioxide into everyday products.

In partnership with the Textile Innovation Engine of North Carolina and North Carolina State University, Mars Materials turned its CO2-derived product into a high-quality raw material for producing carbon fiber, according to a news release. According to the company, the product works "exactly like" the traditional chemical used to create carbon fiber that is derived from oil and coal.

Testing showed the end product met the high standards required for high-performance carbon fiber. Carbon fiber finds its way into aircraft, missile components, drones, racecars, golf clubs, snowboards, bridges, X-ray equipment, prosthetics, wind turbine blades and more.

The successful test “keeps a promise we made to our investors and the industry,” Aaron Fitzgerald, co-founder and CEO of Mars Materials, said in the release. “We proved we can make carbon fiber from the air without losing any quality.”

“Just as we did with our water-soluble polymers, getting it right on the first try allows us to move faster,” Fitzgerald adds. “We can now focus on scaling up production to accelerate bringing manufacturing of this critical material back to the U.S.”

Mars Materials, founded in 2019, converts captured carbon into resources, such as carbon fiber and wastewater treatment chemicals. Investors include Untapped Capital, Prithvi Ventures, Climate Capital Collective, Overlap Holdings, BlackTech Capital, Jonathan Azoff, Nate Salpeter and Brian Andrés Helmick.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.